FDA Approves Combination Treatment Symfi for HIV-1 Infection

By March 28, 2018

Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.

For Those With HIV, Symptom Burden Higher in Women

March 26, 2018

Among respondents to the female survey, the burden scores were higher in women reporting amenorrhea due to natural menopause or hysterectomy (104 respondents) versus the menstruating group (118 respondents) for muscle aches/pains (P=0.05), fatigue (P=0.03), and difficulty falling asleep (P=0.04), independent of age, HIV duration, and number of HIV-associated, non-AIDS conditions.

Raltegravir Labeling Updated With Long-Term Data from Phase 3 HIV Trial

By March 09, 2018

The Isentress (raltegravir) and Isentrress (raltegravir) HD label was recently updated to include Week 96 data from the Phase 3 trial (ONCEMRK).

High Adherence to HIV Preventative Vaginal Ring Seen in Study

By March 08, 2018

As of October 2017 — the cut off date for interim analysis — 89% of the rings returned had residual dapivirine levels consistent with some use in the prior month.

Trogarzo Approved to Treat Multidrug Resistant HIV-1 Infection

By March 06, 2018

The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with MDR HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs.

Biktarvy Found to Be Non-Inferior to Abacavir-Containing Regimen in Phase 3 Study

By March 05, 2018

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50c/mL) on a stable antiretroviral regimen for at least 3 months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

Symfi Lo, Cimduo Will Be Available Soon for HIV Treatment

By March 02, 2018

Symfi Lo will be available in the coming weeks whereas Cimduo is expected in the second quarter of 2018.

Unexpected Toxicities Identified With Concomitant HIV, Tuberculosis Tx Use

By February 09, 2018

The study had to be cut short when 2 of 4 subjects developed serious toxicities following the third isoniazid-rifapentine dose.

FDA Approves Biktarvy to Treat HIV-1 Infection in Adults

By February 08, 2018

Biktarvy combines bictegravir, an integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), two nucleoside reverse transcriptase inhibitors (NRTIs).

Three-Drug Combo Symfi Lo Approved for the Treatment of HIV

By February 07, 2018

Symfi Lo combines efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors.

Edurant Dosing Recommendations Updated for Pregnant HIV Patients

By February 02, 2018

Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely.

Prezcobix Labeling Updated With New Drug Interactions

By January 31, 2018

Prezcobix, a combination of an HIV-1 protease inhibitor and a CYP3A inhibitor, is indicated to treat HIV-1 infection in adults.

Neurodevelopmental Differences Examined in HIV&#43;, HIV-Exposed Children

January 26, 2018

The researchers found that HIV+ and HEU children had lower cognitive and motor scores than their HUU peers within the meta-analysis.

CDC Examines HIV Testing Rates, Reasons For Having Never Been Tested

January 26, 2018

Overall, 38.8% of women and 53.8% of men had never been tested in 2011 to 2015.

HIV Privacy Breach Lawsuit Reaches Settlement

By January 24, 2018

The privacy breach occurred in July 2017, when letters outlining that beneficiaries could now pick up their medications in person were sent in envelopes with large address windows which made private health information visible.

Juluca Labeling Updated to Correct Dosing Separation Information

By January 22, 2018

Juluca was approved as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.

Over one-third of U.S. HIV patients are not vaccinated against hepatitis B

January 10, 2018

One third of HIV patients in the United States remain unvaccinated against hepatitis B.

Single-Dose HIV Med May Deliver Sustained Antiretroviral Concentrations

January 10, 2018

The researchers found that the orally-administered platform delivered three antiretrovirals for up to seven days after a single administration, with week-long systemic drug levels identified.

Teva Launches Generic Reyataz Capsules

By December 27, 2017

Atazanavir Sulfate is an HIV-1 protease inhibitor indicated to treat HIV-1 infection in combination with other antiretrovirals

Hepatitis B Vaccination Often Missed Among HIV Patients

December 27, 2017

More than one-third of adult HIV patients receiving medical care have not been vaccinated

Viread Generic Now Available From Teva

By December 19, 2017

Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor.

Antiretroviral Combination Linked to Increased CKD Risk

By December 08, 2017

The risk of chronic kidney disease (CKD) may be increased in patients living with HIV receiving tenofovir (TDF) with a ritonavir-boosted protease inhibitor compared to those who receive TDF with a non-nucleosidic reverse transcriptase inhibitor (NNRTI)

Cancer Drug Linked to Drastic Depletion of HIV Reservoirs

December 04, 2017

Case report describes smoker with HIV infection receiving nivolumab for non-small-cell lung cancer

New Guidelines Issued for Managing Chronic Pain in HIV Patients

By November 30, 2017

All PWLH should receive brief standardized screening for chronic pain. A biopsychosocial approach should be used; and appropriate monitoring should take place.

CDC: 7-Month Improvement in Time From HIV Infection to Diagnosis

November 29, 2017

Increase in percentage of people at increased risk for HIV who reported getting an HIV test in past year.

First Complete 2-Drug HIV Regimen Gets FDA Approval

By November 21, 2017

Juluca combines dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor.

Early cART, Viral Suppression May Minimize Brain Injury in HIV Patients

November 15, 2017

No significant neuropsychological decline during two-year period with combination antiretroviral therapy

In ART-Treated HIV Patients With GI Discomfort, Consider EPI Assessment

By November 13, 2017

Of 100 participants, 32% had EPI (faecal elastase-1 <200 μg/g) and 20% severe EPI (faecal elastase-1 <100 μg/g).

Direct-Acting Antivirals Beneficial for HCV/HIV Co-Infected Patients

By November 07, 2017

The authors write, "the advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection."

Increasing Resistance to HIV Drugs Threatening Control Efforts

October 26, 2017

WHO has proposed 5-point plan for monitoring, combating, and preventing drug resistance